Previous 10 | Next 10 |
TherapeuticsMD, Inc. (NASDAQ:TXMD) today announced the launch of an underwritten public offering of 22,000,000 shares of its common stock. TherapeuticsMD also expects to grant the underwriters of the offering a 30-day option to purchase up to an additional 3,300,000 shares of common stock at ...
TherapeuticsMD, Inc. (NASDAQ: TXMD) (the “Company”) today announced its estimates of the financial results for the third quarter ended September 30, 2019. For the three months ended September 30, 2019, the Company estimates that its consolidated net revenue from its prescrip...
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced the presentation of ANNOVERA™ (segesterone acetate and ethinyl estradiol vaginal system) findings at the annual meeting of the American Society for Reproductive Medicine (ASRM) being h...
Jennifer Wilson Recognized as a Finalist for Female Executive of the Year TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that Jennifer Wilson, Vice President of Business Development , has been named a Finalist in the Female Execut...
Shares of TherapeuticsMD (NASDAQ: TXMD) gained more than 25% last month, according to data provided by S&P Global Market Intelligence . The pharmaceutical company, which focuses on women's health, published an investor update in mid-September reporting solid progress for its drug portfo...
The following slide deck was published by TherapeuticsMD, Inc. in conjunction with this Read more ...
Introduction to the Positive/Negative Forensic Value Stock Selections This quantitative study continues a series of multi-year test of the top three forensic algorithms used to detect bankruptcy risk, earnings manipulation, and financial irregularities. My forward testing compiles portfolio ...
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that the company will participate in the 2019 Cantor Global Healthcare Conference in New York City. Chief Executive Officer Robert G. Finizio will provide an overview of the company at the co...
Shares of TherapeuticsMD (NASDAQ: TXMD) , a biopharmaceutical company focused on women's health, are rising in response to the company's latest presentation. Investors pleased to see the Imvexxy launch exceeding expectations drove the stock 14.6% higher on Wednesday. TherapeuticsMD had a har...
Gainers: Emmaus Life Sciences ( OTC:EMMA ) +64% . PhaseBio Pharmaceuticals (NASDAQ: PHAS ) +23% . SYNNEX Corporation (NYSE: SNX ) +20% . Contango Oil & Gas Company (NYSEMKT: MCF ) +17% . R.R. Donnelley & Sons Company (NYSE: RRD ) +16% . Comtech Telecommunications (NASDAQ...
News, Short Squeeze, Breakout and More Instantly...
TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the first quarter ended March 31, 2024. First Quarter 2024 Financial Results Net Income (...
• Evaluation of strategic alternatives continues TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2023...